Recorded device evidence

Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue) (K243818): indications, design and recorded evidence

The acquired K243818 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 401 selected decisions under primary code LZA. 401 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 84.0, median 105.0, upper quartile 173.0. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K243818 ↗ · this pageNitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue)2024-12-12 → 2025-01-0827Special
K262542 ↗Biodegradable Nitrile Powder Free Examination Glove, Green; Biodegradable Nitrile Powder Free Examination Glove, Violet Blue Tested for Use With 32 Chemotherapy Drugs, Fentanyl & Gastric Acid Permeation Resistance Claim2026-07-23 → 2026-09-0948Special
K261793 ↗Powder-free Nitrile Examination Gloves Tested for Use With Chemotherapy Drugs and Fentanyl Citrate (Blue and Black Color)2026-05-29 → 2026-09-09103Traditional
K260312 ↗Nitrile Powder Free Examination Glove, Blue Tested for Use with 32 Chemotherapy Drugs and Fentanyl Permeation Resistance Claim; Nitrile Powder Free Examination Glove, Violet Blue Tested for Use with 32 Chemotherapy Drugs, Xylazine, Fentanyl & Gastric Acid2026-01-30 → 2026-09-08221Special
K261749 ↗Cardinal Health Nitrile Blue Examination Gloves Tested for Use with Chemotherapy Drugs and Fentanyl Citrate2026-05-28 → 2026-09-0297Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K243818 · PDF page 7 ↗ Source 2

Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue) is a non-
    sterile disposable device intended for medical purpose that is worn on the examiner’s hand to prevent contamination between
    patient and examiner.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K243818 · PDF page 7 ↗ Source 2

Nitrile  Powder  Free  Examination  Glove  Tested  for  Use  with  Chemotherapy  Drugs  and  Fentanyl  Citrate  (Blue)  is  a
    disposable single-use, non- sterile, blue-colored and powder-free examination glove made from nitrile latex.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K243818 · PDF page 11 ↗ Source 3

The subject device and the predicate device share the same intended use, identical material and identical manufacturing,
   and therefore share the same chemotherapy drug permeation testing, biocompatibility characteristics and compliance with
   ASTM D6319.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {'uncertain_pdf_page': 2}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK243818 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryNitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue) [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantHartalega NGC Sdn. Bhd. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeLZA [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2025-01-08 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeSpecial [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2024-12-12 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

Work packages and dependencies

What needs to happen first

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[27071] · record db14257393f2da3c68036e55d50e21dd6a91c33aeb4916e12f2df865d464959f
  • [4] Complete results array / fda-decision-context:K243818 · record whole dataset partition

FDA 510(k) summary — K243818 ↗

Thu, 06 Feb 2025 14:13:22 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot cfbdfd2edbeef8d0d1db04f3d9c052bbaff60c47ee5fae5ef219164ea01ee72d

  • [2] PDF page 7 · record e216e012072f5ef2ede036b34dea2e425b8e737c23324a5ba9a1f6ff36d6b3be
  • [3] PDF page 11 · record 353066a3b6fbffea99781d0292ae56911576757cbe8b247c828d34e179b5458d

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services

Biocompatibility Testing (ISO 10993 Program)